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 ABSTRACT. Interest in nuclear imaging of poly(ADP-ribose) polymerase-1 (PARP-1) has 
grown in recent years due to the ability of PARP-1 to act as a biomarker for glioblastoma and 
increased clinical use of PARP-1 inhibitors. This study reports the identification of a lead 
iodinated analog 5 of the clinical PARP-1 inhibitor olaparib as a potential single-photon 
emission computed tomography (SPECT) imaging agent. Compound 5 was shown to be a potent 
PARP-1 inhibitor in cell-free and cellular assays, and it exhibited mouse plasma stability but 
approximately 3-fold greater intrinsic clearance when compared to olaparib. An 123I-labeled 
version of 5 was generated using solid state halogen exchange methodology. Ex vivo 
biodistribution studies of [123I]-5 in mice bearing subcutaneous glioblastoma xenografts revealed 
that the tracer had the ability to be retained in tumour tissue and bind to PARP-1 with specificity. 
These findings support further investigations of [123I]-5 as a non-invasive PARP-1 SPECT 
imaging agent. 
 
 
 
 
 
 
 
 
 INTRODUCTION. 
Poly(ADP-ribose) polymerase 1 (PARP-1) is a nuclear protein responsible for various 
cellular processes including repair of single-stranded DNA breaks (SSB), cell division, gene 
transcription and apoptosis regulation.1 The role of PARP-1 in DNA repair has made it a highly 
pursued therapeutic target resulting in the development of numerous PARP-1 inhibitors (PARPi) 
with cancer treatment in mind. Initial therapeutic strategies involved targeting cancers that are 
deficient in the BRCA-1 and BRCA-2 genes that encode proteins with roles in homologus 
recombination repair of double-stranded DNA breaks (DSB). The combination of PARPi 
induced deficiency of SSB repair and impaired DSB repair generates synthetic lethality in BRCA 
mutated cancer cells while healthy tissues with intact BRCA function were not affected.2±3 
Compound 1 (olaparib) (Figure 1) is a PARPi that has recently been licenced in the EU and US 
as monotherapy for advanced BRCA deficient ovarian cancer4 making it the most clinically 
advanced compound in its class.  
In addition to synthetic lethality, PARPi are also being clinically assessed as adjuncts to 
chemotherapy where inhibition of PARP-1 mediated DNA repair sensitizes cancer cells to 
cytotoxic agents. However, a number of early phase clinical trials have reported severe bone 
marrow toxicity with such therapeutic combinations5±10 which could in part be attributed to sub-
optimal dosing schedules.8 Non-invasive in vivo imaging of PARP-1 using a radiolabeled PARPi 
and techniques such as Positron Emission Tomography (PET) or Single-Photon Emission 
Tomography (SPECT) could be used to assess the duration of PARP-1 inhibition in different 
tissues. This could subsequently guide dosing decisions for PARPi when given in combination 
with chemotherapy such that tumour cytotoxicity is maximized and bone marrow toxicity is 
minimized. Furthermore, molecular imaging of PARP-1 could be utilized by clinicians to 
 evaluate the levels of PARP-1, as well as the extent of PARP-1 inhibition, in tumors in order to 
eliminate patients that are unlikely to respond to PARP-1 inhibitor therapy. There is a clinical 
need for this kind of information as the use of PARPi as mono- and combination therapy is 
becoming more prominent. PARP-1 could also be used as a molecular imaging biomarker for 
visualization of glioblastoma (GBM) which is known to overexpress PARP-1 in contrast to 
surrounding brain tissue where PARP-1 levels are low.11 This type of imaging could be exploited 
for pre-surgical planning of GBM treatment, since conventional magnetic resonance imaging 
techniques lack the necessary sensitivity and specificity to delineate tumor from non-tumor 
tissue.12 
With applications such as these it is not surprising that molecular imaging tracers for 
PARP-1 are being developed. At the time of writing all current PARP-1 tracers are being 
developed for the PET imaging modality (compounds 2±4, Figure 2)13±15 and to the best of our 
knowledge there are no SPECT radiotracers in development. In recent years PET imaging has 
gained a lot of traction in clinical environments due to shorter scan durations, superior sensitivity 
and spatial resolution, and availability of combined modality imaging (e.g. PET/CT) when 
compared to SPECT.16±17 However, hybrid SPECT/CT devices are now in general clinical use 
and new technology is emerging which has the capability to significantly improve spatial 
resolution.17 An important advantage of SPECT over PET is the ability to perform simultaneous 
dual-tracer imaging16 which could be utilized as a powerful tool when comparing existing to 
novel radiotracers. Furthermore, the established nature of this molecular imaging modality 
means that clinical SPECT scanners are currently more widely available than PET scanners.18 
For these reasons, the SPECT modality is likely to remain a key component of nuclear medicine 
 for many years to come and radiotracer development for SPECT imaging should not be 
neglected. 
Therefore, we proposed to use the structure of the clinical PARPi 1 in the pursuit of a 
novel PARP-1 SPECT imaging radiotracer. It has been shown that binding of 1 to the PARP-1 
active site can tolerate structural modifications in the cyclopropane bearing region.19±20 Utilizing 
this, we report the synthesis of a small library of novel cold (non-radioactive) iodinated analogs 
of 1 with structural variance in the cyclopropane region, which were designed to represent 
potential PARP-1 SPECT imaging agents. An iodinated compound is extremely versatile, having 
the potential to incorporate different iodine radionuclides, such as 123I for SPECT imaging, 124I 
for PET imaging and 131I for radiotherapeutic application. We describe the physiochemical 
parameters and activity against PARP-1 of these compounds followed by the assessment of 
plasma and metabolic stability of the lead analog 5. The radioiodination methodology and 
subsequent ex vivo biodistribution of the potential PARP-1 SPECT tracer [123I]-5 in mice bearing 
subcutaneous glioblastoma xenografts are also described. 
 
RESULTS AND DISCUSSION. 
Chemistry. The penultimate compound 6 (Table 1) which was used to access 1 and its 
analogs was synthesized using a slightly modified route to that described previously by Menear 
et al
20 (see supplementary information for details). An amide coupling reaction between 6 and 
the commercially available cyclopropane carboxylic acid formed 1. Iodinated analogs (5 and 7±
12) of 1 were accessed by either amide or N-sulfonyl coupling of the penultimate compound 6 
with the corresponding commercially available carboxylic acid or sulfonyl chloride compounds 
 respectively as shown in Table 1. This approach allowed rapid access to a small library of cold 
iodinated compounds representing potential PARP-1 SPECT imaging agents. 
In vitro characterization. Compounds 5 and 7±12 were screened in vitro for their ability 
to inhibit PARP-1 in a cell-free system and for their lipophilicity (log Poct) and percentage 
plasma protein binding (%PPB) parameters using high performance liquid chromatography. The 
results of this screen are outlined in Table 1. The iodinated compounds exhibited low nanomolar 
cell-free PARP-1 IC50 values confirming that structural variance in the cyclopropane region of 1 
had only a minor influence on PARP-1 inhibition potency.19±20 The analogs also showed greater 
log Poct ( 2.95) and %PPB ( 96.1%) values when compared to 1 (log Poct = 1.95, %PPB = 
75.9%). The increase in both parameters can be partly attributed to the presence of the lipophilic 
iodine-bearing benzyl moieties as plasma protein binding interactions are hydrophobic in 
nature.21 Despite the increase in lipophilic properties, the log Poct values of compounds 5, 7 and 9 
were within the optimal range (log Poct = 1.5±3.0) for passage across cellular membranes22 which 
is important as PARP-1 is localized within cellular nuclei. Under normal circumstances large 
macromolecules such as plasma proteins are unable to penetrate into the brain due to the 
presence of the Blood-Brain Barrier (BBB). However, numerous pathologies of the brain 
including tumors are associated with disruptions of the BBB.23 This, coupled with the fact that 
tumors are known to actively take up plasma proteins24 has made it possible to target gliomas 
with fluorescent- and radiolabelled human plasma protein conjugates for fluorescent25 and 
SPECT26 imaging respectively. It is therefore proposed that the extensive plasma protein binding 
of analogs 5 and 7±12 could provide an additional means of passive targeting for the molecular 
imaging of tumors including GBM. 
 Compound 5 was selected as the lead candidate for further assessment due to its cell-free 
PARP-1 inhibitory potency (cell-free IC50 3.3 nM), optimal lipophilic properties (log Poct = 3.0) 
and the radiochemically accessible para position of the iodine atom. Cellular IC50 values in 
primary G7 and established T98G human glioblastoma cell lines were ascertained in order to 
confirm the PARP-1 inhibitory potency of 5 in cellular systems (Table 2). A slight reduction in 
cellular compared with cell-free PARP-1 inhibitory potency was observed (3.3 nM vs. 7.0 nM in 
G7 and 7.4 nM in T98G cells) which can be explained by the fact that in the former case activity 
requires cellular penetration and retention, unlike the cell-free assay. Despite this slight reduction 
in potency, 5 remained an effective PARP-1 inhibitor in living cells, confirming its ability to 
enter tumour cells in vitro. 
The stability of 5 was investigated in presence of mouse plasma proteins and human liver 
microsomes. Compound 5 was shown to be stable in mouse plasma over a 20 h period with no 
noticeable degradation taking place (Table 2). The intrinsic clearance (Clint), an in vitro 
parameter of metabolic stability,27 of 5 was markedly greater than that of 1 (Clint = 85 ± 4 vs. 29 
± 4 ȝL/min/mg) suggesting more rapid in vivo metabolism of the analog (Table 2). The terminal 
aromatic-halide moiety of 5 is likely to undergo liver enzyme oxidation and dehalogenation, 
which might explain the observed reduction in metabolic stability.28 This is in contrast to the 
metabolically stable cyclopropane moiety of 1.29 Furthermore, since a positive correlation exists 
between lipophilicity and rate of metabolism, the increase in log Poct of 5 may have also been a 
contributing factor to the increase in Clint.
21 
Radiochemistry. Following in vitro characterization of 5 focus was shifted towards 
generating a radioiodinated version of this compound. Initial efforts to obtain the stannyl 
 precursor for the destannylation radioiodindation of 5 were unsuccessful. Therefore, solid state 
aromatic halogen exchange radioiodination methodology was investigated based on our past 
successful experiences with this technique.30 The bromine analog 13, accessed by amide 
coupling of the penultimate compound 6 with commercially available 4-bromobenzoic acid, was 
used as the radiolabelling precursor (Table 3). For practical reasons, optimization of the 
radiolabelling reaction was performed using the long lived 125I-radionuclide (half-life of 125 I = 
60.1 days vs. 123I = 13.2 hours). The reaction conditions described by Gildersleeve et al31 (entry 
1) were used as a starting point which allowed for an 125I incorporation yield of 38% (n = 1). By 
increasing the temperature and the reaction time (entry 3) an improved yield of 90% (n = 1) was 
achieved. The drop in radioiodide incorporation in the absence of air (entry 4) was not 
unexpected as a mildly oxidizing environment is necessary for efficient solid state halogen 
exchange to take place.32 The conditions described in entry 3 were identified as optimal and were 
used for 123I-radiolabelling (Scheme 1) giving access to the potential SPECT imaging agent 
[123I]-5 in a non-decay corrected end of synthesis yield of 36.5 ± 7.2% (n = 6) and a specific 
activity of >19.0 ± 10.3 Ci/ȝmol (n = 4). 
Ex vivo biodistribution. In order to assess the behaviour of [123I]-5 in vivo the 
biodistribution of the radioligand was investigated in female nude mice bearing subcutaneous 
human glioblastoma xenografts by gamma-counting of harvested animal materials and tissues 
30, 60 and 120 min after intravenous injection of the radiotracer. The large amounts of 
radioactivity present in the liver and small bowel matter 30 min after injection and the 
subsequent gradual increase of radioactivity in solid feces were indicative of rapid hepatobilliary 
clearance of [123I]-5 (Figure 3). This type of clearance is in line with previous observations made 
for 1.33 Despite rapid in vivo clearance, a significant increase in the mean ratio of percentage 
 injected dose per gram (%ID/g) of tumor to muscle was observed between the 30 and 120 min 
timepoints (2.15 ± 0.47 to 5.61 ± 1.99) providing clear evidence of radioligand retention within 
the tumor (unpaired t test: P = 0.036). Immunohistochemical staining of tumor tissue showed 
high levels of proliferative cells and PARP-1 expression. This is in contract to muscle tissue 
where the proliferative marker (Ki67) and PARP-1 were not detectable (Figure 4). The negligible 
uptake of [123I]-5 in the brain can be explained by low PARP-1 expression in healthy brain tissue 
and,11 with the exception of log Poct, physiochemical parameters that fall outside of those optimal 
for BBB penetration (optimal parameters: log Poct = 2±321, MW <45034, %PPB <95%35). 
Chalmers et al reported similar findings which showed that after a single dose of [14C]-1 there 
was no detectable radioactivity in the central nervous system of subcutaneous colorectal cancer 
xenograft bearing rats. However, the authors were able to show therapeutic levels of 1 in 
resected GBM specimens from patients who received oral doses of the drug.36 Therefore, we 
hypothesize that BBB disruptions associated with GBM23 will allow for uptake of [123I]-5 in 
brain tumor tissue. It is important to confirm that the uptake of [123I]-5 in tumor was due to the 
specific binding of the radioligand to PARP-1. This was achieved by blocking PARP-1 binding 
sites through the pre-treatment of subcutaneous tumor bearing mice with 50 mg/kg unlabelled 
compound 1 intraperitonally 20 min prior to radiotracer administration (Figure 5).  Pre-blockade 
with 1 resulted in a significant decrease in the ratio of %ID/g of tumour to muscle from 2.59 ± 
0.06 to 1.30 ± 0.13 when compared to the vehicle treated cohort (unpaired t test: P = 0.001). This 
observation confirms the specificity of [123I]-5 for PARP-1 in vivo. 
 
 
 CONCLUSIONS. 
In an effort to develop a novel PARP-1 SPECT radiotracer we have generated a small library of 
cold iodinated analogs based on the clinical PARP-1 inhibitor 1, designed to represent potential 
SPECT imaging agents. In vitro characterization of these compounds led to the identification of 
5 as a lead candidate due to its low nanomolar PARP-1 cell-free IC50. The compound was 
revealed to be a potent PARP-1 inhibitor in two human glioblastoma cell lines and it was stable 
in mouse plasma, but exhibited approximately 3-fold greater in vitro clearance when compared 
to 1. Radioiodination methodology was developed and the in vivo behaviour of [123I]-5 was 
assessed in mice bearing a subcutaneous human glioblastoma xenograft model. Ex vivo 
biodistribution revealed rapid hepatobiliary clearance of [123I]-5. Despite that, the radioligand 
exhibited tumor tissue retention and specific binding to PARP-1 in vivo. Collectively, these 
findings support further in vivo evaluation of [123I]-5 as a PARP-1 SPECT imaging agent. 
EXPERIMENTAL SECTION. 
All reagents and starting materials were obtained from commercial sources and used as 
received. All dry solvents were purified using a solvent purification system. All reactions were 
performed under an atmosphere of argon unless otherwise mentioned. Flash column 
chromatography was performed using Fisher matrix silica gel 60 (35±70 Pm). Macherey-Nagel 
aluminium-backed plates pre-coated with silica gel 60F254 were used for thin layer 
chromatography and were visualized with a UV lamp or by staining with potassium 
permanganate. 1H NMR spectra were recorded on a Bruker DPX 400 spectrometer or a Bruker 
500 spectrometer and data are reported as follows: chemical shift in ppm relative to Me4Si or the 
solvent (CDCl3, G 7.26 ppm, CD3OD, G 3.31 ppm or DMSO-G6, G2.50 ppm) as the internal 
 standard, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet or overlap of 
nonequivalent resonances, integration). 13C NMR spectra were recorded on a Bruker DPX NMR 
spectrometer at either 101 or 126 MHz and data are reported as follows: chemical shift in ppm 
relative to Me4Si or the solvent as internal standard (CDCl3, G 77.2 ppm, CD3OD, G 49.0 ppm or 
DMSO-G6, G 39.5 ppm), multiplicity with respect to proton (deduced from DEPT experiments, C, 
CH, CH2 or CH3). Infrared spectra were recorded using a Shimadzu IRPrestige-21 spectrometer; 
wavenumbers are indicated in cm±1. Mass spectra were recorded using electron impact, chemical 
ionization or electrospray techniques. HRMS spectra were recorded using a JEOL JMS-700 
spectrometer. Melting points are uncorrected. All compounds used for biological testing 
exhibited >95% purity as per HPLC. Mice used for in vivo studies were housed in individually 
ventilated cages and had access to sterilized food and water ad libitum. All animal experiments 
were carried out in compliance with UK Home Office regulations. 
 
4->¶-¶¶-Cyclopropanecarbonylpiperazine-¶¶-carbonyl)-¶-fluorobenzyl]-2H-phthalazin-
1-one (1).
20
 7RD VROXWLRQRIF\FORSURSDQRLFDFLG ȝ/PPRO LQ'0) mL) was 
added Et31ȝ/PPROIROORZHGE\+%78PJPPRODQGWKHPL[WXUH
was stirred at room temperature for 1 h. Following this 6 (50.0 mg, 0.137 mmol) was then added 
and the mixture was stirred for a further 72 h. The crude product was extracted into CHCl3 (3 × 
10 mL) and the organic layer was washed with water (6 × 20 mL), dried with MgSO4, filtered 
and concentrated in vacuo to give a yellow solid. Purification by flash column chromatography 
(MeOH/CH2Cl2, 4:96) gave 1 (30 mg, 51%) as a white foam. 
1H NMR spectra showed a 3:2 
mixture of rotamers. Only data for the major rotamer were recorded. 1H NMR (400 MHz, 
CDCl3) į 0.67(?0.86 (m, 2H), 0.97(?1.03 (m, 2H), 1.75 (br s, 1H), 3.20(?3.43 (m, 2H), 3.51(?3.93 
 (m, 6H), 4.29 (s, 2H), 7.04 (t, J 8.9 Hz, 1H), 7.29(?7.41 (m, 2H), 7.67(?7.82 (m, 3H), 8.43(?8.51 
(m, 1H), 11.12 (br s, 1H); 13C NMR (101 MHz, CDCl3) į7.8 (2 × CH2), 11.2 (CH), 37.8 (CH2), 
41.8 (CH2), 42.4 (CH2), 45.3 (CH2), 47.0 (CH2), 116.3 (CH, d, JC-C-F 22.3 Hz), 123.9 (C, d, JC-C-F 
18.3 Hz), 125.1 (CH), 127.3 (CH), 128.5 (C), 129.4 (CH), 129.7 (C), 131.7 (CH), 131.8 (CH, d, 
JC-C-C-F 8.1 Hz), 133.8 (CH), 134.5 (C, d, JC-C-C-C-F 3.4 Hz), 145.6 (C), 157.2 (C, d, JC-F 247.4 
Hz), 160.7 (C), 165.3 (C), 172.4 (C); HRMS (ESI) calcd for C24H23FN4NaO3 (MNa
+), 457.1646, 
found 457.1636. 
4->¶->¶¶-¶¶¶-Iodobenzoyl)piperazine-¶¶-carbonyl]-¶-fluorobenzyl]-2H-phthalazin-1-one 
(5). To a solution of 4-iodobenzoic acid (42.0 mg, 0.170 mmol) in DMF (7 mL) was added Et3N 
ȝ/PPROIROORZHGE\+%78PJPPRODQGWKHPL[WXUHZDVVWLUUHG
at room temperature for 2 h. Following this 6 (60.0 mg, 0.170 mmol) was added and the mixture 
was stirred for a further 48 h. Water (14 mL) was then added, followed by 1 h of stirring after 
which the mixture was cooled to 0 °C. The resulting precipitate was collected by vacuum 
filtration and washed with Et2O (4 × 10 mL) and hexane (4 × 10 mL). Purification by flash 
column chromatography (MeOH/CH2Cl2, 4:96) gave 5 (34.8 mg, 34%) as a white foam. IR 
(neat) 3198, 3003, 2899, 1628, 1587, 1427, 1001, 747 cm±1; 1H NMR (400 MHz, CDCl3) į 3.14(?
4.02 (m, 8H), 4.29 (s, 2H), 7.03 (t, J 7.8 Hz, 1H), 7.14 (d, J 8.0 Hz, 2H), 7.29(?7.37 (m, 2H), 
7.67(?7.84 (m, 5H), 8.42(?8.51 (m, 1H), 10.96 (s, 1H); 13C NMR (101 MHz, CDCl3) į37.8 (CH2), 
42.2 (2 × CH2), 47.3 (2 × CH2), 96.6 (C), 116.3 (CH, d, JC-C-F 21.7 Hz), 123.6 (C, d, JC-C-F 17.7 
Hz), 125.1 (CH), 127.3 (CH), 128.4 (C), 128.9 (2 × CH), 129.4 (CH, d, JC-C-C-F 3.6 Hz), 129.6 
(C), 131.8 (CH), 131.9 (CH, d, JC-C-F 8.0 Hz), 133.8 (CH), 134.5 (C), 134.6 (C, d, JC-C-C-C-F 3.7 
Hz), 138.0 (2 × CH), 145.6 (C), 157.1 (C, d, JC-F 247.1 Hz), 160.7 (C), 165.3 (C), 169.8 (C); 
HRMS (ESI) calcd for C27H22FIN4NaO3 (MNa
+), 619.0613, found 619.0597. 
 4->¶->¶¶-¶¶¶-Iodobenzoyl)piperazine-¶¶-carbonyl]-¶-fluorobenzyl]-2H-phthalazin-1-one 
(7). The reaction was carried out as described for 5 using a solution of 3-iodobenzoic acid (34.0 
mg, 0.137 mmol) in DMF (3 mL), Et31ȝ/PPRO+%78.0 mg, 0.151 mmol) 
and 6 (50.0 mg, 0.137 mmol). Purification by flash column chromatography (MeOH/CH2Cl2, 
4:96) gave 7 (36.4 mg, 45%) as a white foam. IR (neat) 3190, 3053, 2862, 1628, 1559, 1427, 
1252, 1005, 791, 729 cm±1; 1H NMR (400 MHz, CDCl3) į 3.16(?4.01 (m, 8H), 4.29 (s, 2H), 7.03 
(br s, 1H), 7.15 (br s, 1H), 7.27(?7.39 (m, 3H), 7.67(?7.82 (m, 5H), 8.42(?8.49 (m, 1H), 10.70 (s, 
1H); 13C NMR (101 MHz, CDCl3) į37.8 (CH2), 42.2 (2 × CH2), 47.4 (2 × CH2), 94.5 (C), 116.3 
(CH, d, JC-C-F 21.7 Hz), 123.6 (C, d, JC-C-F 17.7 Hz), 125.1 (CH), 126.2 (CH), 127.3 (CH), 128.4 
(C), 129.4 (CH, d, JC-C-C-F 3.6 Hz), 129.6 (C), 130.4 (CH), 131.8 (CH), 131.9 (CH, d, JC-C-C-F 8.0 
Hz), 133.8 (CH), 134.6 (C, d, JC-C-C-C-F 3.9 Hz), 136.0 (CH), 137.1 (C), 139.2 (CH), 145.6 (C), 
157.1 (C, d, JC-F 247.1 Hz), 160.8 (C), 165.3 (C), 168.8 (C); HRMS (ESI) calcd for 
C27H22FIN4NaO3 (MNa
+), 619.0613, found 619.0605. 
4->¶->¶¶-¶¶¶-Iodo-¶¶¶-methylbenzoyl)piperazine-¶¶-carbonyl]-¶-fluorobenzyl]-2H-
phthalazin-1-one (8). To a solution of 3-iodo-4-methylbenzoic acid (36.0 mg, 0.137 mmol) in 
DMF (3 mL) was added Et31  ȝ/  PPRO IROORZHG E\ +%78  PJ 
mmol) and the mixture was stirred at room temperature for 1 h. Following this, 6 (50.0 mg, 0.137 
mmol) was then added and the mixture was stirred for a further 22 h at 40 °C. The mixture was 
cooled to room temperature and water (6 mL) was added, followed by 1 h of stirring after which 
the mixture was cooled to 0 °C. The resulting precipitate was collected by vacuum filtration and 
dissolved in CHCl3 (10 mL). The organic layer was washed with water (3 × 20 mL) and 
concentrated in vacuo. Purification by flash column chromatography (MeOH/CH2Cl2, 3:97) gave 
8 (40.0 mg, 48%) as a white foam. IR (neat) 3203, 3011, 2893, 1629, 1425, 1252, 1006, 746 cm±
 1; 1H NMR (400 MHz, CDCl3) į2.44 (s, 3H), 3.13(?4.05 (m, 8H), 4.27 (s, 2H), 7.03 (t, J 8.4 Hz, 
1H), 7.23(?7.37 (m, 4H), 7.67(?7.80 (m, 3H), 7.85 (s, 1H), 8.43(?8.49 (m, 1H), 10.85 (s, 1H); 13C 
NMR (101 MHz, CDCl3) į 28.2 (CH3), 37.8 (CH2), 42.3 (2 × CH2), 47.1 (2 × CH2), 101.1 (C), 
116.3 (CH, d, JC-C-F 22.0 Hz), 123.7 (C, d, JC-C-F 17.6 Hz), 125.1 (CH), 127.0 (CH), 127.3 (CH), 
128.4 (C), 129.4 (CH, d, JC-C-C-F 3.2 Hz), 129.6 (C), 129.8 (CH), 131.8 (CH), 131.9 (CH, d, JC-C-
C-F 7.8 Hz), 133.8 (CH), 134.2 (C), 134.6 (C, d, JC-C-C-C-F 3.8 Hz), 137.6 (CH), 143.9 (C), 145.6 
(C), 157.1 (C, d, JC-F 249.9 Hz), 160.8 (C), 165.3 (C), 168.9 (C); HRMS (ESI) calcd for 
C28H24FIN4NaO3 (MNa
+), 633.0769, found 633.0759. 
4->¶->¶¶-¶¶¶-Iodo-¶¶¶-methoxybenzoyl)piperazine-¶¶-carbonyl]-¶-fluorobenzyl]-2H-
phthalazin-1-one (9). The reaction was carried out as described for 5 using a solution of 3-iodo-
4-methoxybenzoic acid (76.0 mg, 0.273 mmol) in DMF (5 mL), Et31ȝ/, 0.437 mmol), 
HBTU (114 mg, 0.300 mmol) and 6 (100 mg, 0.273 mmol). Purification by flash column 
chromatography (MeOH/CH2Cl2, 3:97) gave 9 (44.5 mg, 26%) as a white foam. IR (neat) 3192, 
3009, 2897, 1628, 1593, 1425, 1256, 1005, 747 cm±1; 1H NMR (400 MHz, CDCl3) į 3.34 (br s, 
2H), 3.45(?3.85 (m, 6H), 3.90 (s, 3H), 4.29 (s, 2H), 6.82 (d, J 8.3 Hz, 1H), 7.03 (t, J 8.7 Hz, 1H), 
7.29(?7.36 (m, 2H), 7.40 (dd, J 8.3, 2.0 Hz, 1H), 7.68(?7.81 (m, 3H), 7.85 (d, J 2.0 Hz, 1H), 8.43(?
8.50 (m, 1H), 10.82 (s, 1H); 13C NMR (101 MHz, CDCl3) į37.8 (CH2), 42.3 (2 × CH2), 47.2 (2 
× CH2), 56.7 (CH3), 86.0 (C), 110.6 (CH), 116.3 (CH, d, JC-C-F 21.7 Hz), 123.6 (C, d, JC-C-F 17.7 
Hz), 125.1 (CH), 127.4 (CH), 128.5 (C), 129.1 (C), 129.3 (CH), 129.4 (CH, d, JC-C-C-F 3.6 Hz), 
129.7 (C), 131.8 (CH), 131.9  (CH, d, JC-C-C-F 8.0 Hz), 133.8 (CH), 134.6 (C, d, JC-C-C-C-F 3.9 Hz), 
138.8 (CH), 145.6 (C), 157.1 (C, d, JC-F 247.1 Hz), 159.7 (C), 160.6 (C), 165.3 (C), 169.0 (C); 
HRMS (ESI) calcd for C28H24FIN4NaO4 (MNa
+), 649.0718, found 649.0713. 
 4->¶->¶¶->¶¶¶-¶¶¶¶-Iodophenyl)acetyl]piperazine-¶¶-carbonyl]-¶-fluorobenzyl]-2H-
phthalazin-1-one (10). The reaction was carried out as described for 5 using a solution of 3-
iodophenylacetic acid (72.0 mg, 0.273 mmol) in DMF (5 m/ WULHWK\ODPLQH  ȝ/ 
mmol), HBTU (114 mg, 0.300 mmol) and 6 (100 mg, 0.273 mmol). Purification by flash column 
chromatography (MeOH/CH2Cl2, 3:97) gave 10 (67.0 mg, 40%) as a white foam. NMR spectra 
showed a 55:45 mixture of rotamers. Only data for the major rotamer were recorded. IR (neat) 
3190, 3005, 2899, 1632, 1589, 1433, 1223, 1013, 748 cm±1; 1H NMR (400 MHz, CDCl3) į3.27 
(br s, 2H), 3.39 (t, J 4.6 Hz, 2H), 3.50(?3.90 (m, 6H), 4.28 (s, 2H), 6.97(?7.10 (m, 2H), 7.14(?7.24 
(m, 1H), 7.29(?7.37 (m, 2H), 7.53(?7.63 (m, 2H), 7.67(?7.73 (m, 1H), 7.74(?7.81 (m, 2H), 8.43(?
8.50 (m, 1H), 10.90 (br s, 1H); 13C NMR (101 MHz, CDCl3) į 37.8 (CH2), 40.3 (CH2), 41.6 
(CH2), 42.1 (CH2) 45.8 (CH2), 46.8 (CH2), 94.8 (C), 116.3 (CH, d, JC-C-F 21.7 Hz), 123.5 (C, d, 
JC-C-F 17.7 Hz), 125.0 (CH), 127.2 (CH), 128.1 (CH), 128.3 (C), 129.3 (CH, d, JC-C-C-F 3.3 Hz), 
129.6 (C), 130.6 (CH), 131.7 (CH), 131.9 (CH, d, JC-C-C-F 7.9 Hz), 133.8 (CH), 134.6 (C, d, JC-C-
C-C-F 3.2 Hz), 136.3 (CH), 136.9 (C), 137.7 (CH), 145.6 (C), 157.0 (C, d, JC-F 247.8 Hz), 161.0 
(C), 165.3 (C), 169.1 (C); HRMS (ESI) calcd for C28H24FIN4NaO3 (MNa
+), 633.0769, found 
633.0750. 
4->¶->¶¶->¶¶¶-¶¶¶¶-Iodophenoxy)acetyl]piperazine-¶¶-carbonyl]-¶-fluorobenzyl]-2H-
phthalazin-1-one (11). The reaction was carried out as described for 5 using a solution of 4-
iodophenoxyacetic acid (76.0 mg, 0.273 mmol) in DMF (5 mL), Et31ȝ/PPRO
HBTU (114 mg, 0.300 mmol) and 6 (100 mg, 0.273 mmol). Purification by flash column 
chromatography (MeOH/CH2Cl2, 4:96) gave 11 (55.0 mg, 32%) as a white foam. NMR spectra 
showed a 55:45 mixture of rotamers. Only data for the major rotamer were recorded. IR (neat) 
3167, 3007, 2901, 1634, 1585, 1485, 1431, 1217, 1009, 745 cm±1; 1H NMR (400 MHz, CDCl3) į
 3.22 (br s, 2H), 3.40(?3.83 (m, 6H), 4.22 (s, 2H), 4.64 (s, 2H), 6.67 (d, J 6.7 Hz, 2H), 6.96 (t, J 
8.6 Hz, 1H), 7.23(?7.31 (m, 2H), 7.48 (t, J 9.2 Hz, 2H), 7.60(?7.75 (m, 3H), 8.37(?8.44 (m, 1H), 
11.23 (s, 1H); 13C NMR (101 MHz, CDCl3) į 37.7 (CH2), 42.4 (2 × CH2), 45.2 (CH2), 46.8 
(CH2), 67.7 (CH2), 84.4 (C), 116.3 (CH, d, JC-C-F 22.1 Hz), 117.0 (2 × CH), 123.5 (C, d, JC-C-F 
17.6 Hz), 125.1 (CH), 127.3 (CH), 128.4 (C), 129.3 (CH, d, JC-C-C-F 3.4 Hz), 129.6 (C), 131.7 
(CH), 131.9 (CH, d, JC-C-C-F 7.9 Hz), 133.8 (CH), 134.6 (C, d, JC-C-C-C-F 3.6 Hz), 138.6 (2 × CH), 
145.6 (C), 157.0 (C, d, JC-F 247.4 Hz), 157.6 (C), 160.9 (C), 165.3 (C), 166.5 (C); HRMS (ESI) 
calcd for C28H24FIN4NaO4 (MNa
+), 649.0718, found 649.0714. 
4->¶->¶¶->¶¶¶-Iodobenzenesulfonyl]piperazine-¶¶-carbonyl]-¶-fluorobenzyl]-2H-
phthalazin-1-one (12). Et31ȝ/PPRODQG-iodobenzenesulfonyl chloride (50.0 
mg, 0.164 mmol) were added to a solution of 6 (50.0 mg, 0.137 mmol) in CH2Cl2 (3 mL). The 
mixture was stirred at room temperature for 6 h after which, water (3 mL) was added. The crude 
product was extracted into CH2Cl2 (3 × 10 mL), dried with Na2SO4, filtered and concentrated in 
vacuo. Purification by flash column chromatography (MeOH/CH2Cl2, 3:97) gave 12 (45.0 mg, 
52%) as a white foam. IR (neat) 3185, 3006, 2895, 1637, 1568, 1438, 1349, 1164, 1005, 742 cm±
1; 1H NMR (400 MHz, CDCl3) į2.97 (t, J 4.8 Hz, 2H), 3.09 (br s, 2H), 3.39 (br s, 2H), 3.85 (br 
s, 2H), 4.27 (s, 2H), 7.00 (t, J 8.8 Hz, 1H), 7.24(?7.34 (m, 2H), 7.40(?7.46 (m, 2H), 7.66(?7.72 (m, 
1H), 7.73(?7.80 (m, 2H), 7.88(?7.93 (m, 2H), 8.44(?8.51 (m, 1H), 11.31 (s, 1H); 13C NMR (101 
MHz, CDCl3) į 37.8 (CH2), 41.5 (CH2), 45.8 (CH2), 46.2 (CH2), 46.6 (CH2), 101.0 (C), 116.3 
(CH, d, JC-C-F 21.8), 123.4 (C, d, JC-C-F 17.9 Hz), 125.1 (CH), 127.3 (CH), 128.4 (C), 129.1 (2 × 
CH), 129.5 (CH, d, JC-C-C-F 3.5 Hz), 129.7 (C), 131.8 (CH), 132.0 (CH, d, JC-C-C-F 8.1 Hz), 133.8 
(CH), 134.6 (C, d, JC-C-C-C-F 3.2 Hz), 135.4 (C), 138.7 (2 × CH), 145.6 (C), 156.9 (C, d, JC-F 
 247.7 Hz), 160.8 (C), 165.0 (C); HRMS (ESI) calcd for C26H22FIN4NaO4S (MNa
+), 655.0283, 
found 655.0274. 
4->¶->¶¶-¶¶¶-Bromobenzoyl)piperazine-¶¶-carbonyl]-¶-fluorobenzyl]-2H-phthalazin-1-
one (13). The reaction was carried out as described for 5 using a solution of 4-bromobenzoic 
acid (165 mg, 0.820 mmol) in DMF (10 mL), Et31ȝ/PPRO+%78PJ
mmol). Following the addition of 6 (300 mg, 0.820 mmol), the mixture was stirred at room 
temperature for 72 h, after which water (30 mL) was added and the solution was stirred for an 
additional 1 h. The mixture was cooled to 0 °C and the resulting precipitate was collected by 
vacuum filtration, washed with water (4 × 30 mL) and dried in vacuo to yield 13 (424 mg, 94%) 
as a yellow-white foam. IR (neat) 3233, 2934, 1668, 1622, 1593, 1460, 1433, 1269, 1221, 1003, 
772 cm±1; 1H NMR (500 MHz, CDCl3) į3.20±4.00 (m, 8H), 4.31 (s, 2H), 7.06 (br s, 1H), 7.27±
7.39 (m, 4H), 7.52(?7.63 (m, 2H), 7.70(?7.75 (m, 1H), 7.75(?7.78 (m, 2H), 8.46(?8.53 (m, 1H), 
10.99 (s, 1H); 13C NMR (126 MHz, CDCl3) į 37.7 (CH2), 42.2 (2 × CH2), 47.0 (2 × CH2), 116.2 
(CH, d, JC-C-F 23.1 Hz), 123.5 (C, d, JC-C-F 17.6 Hz), 124.6 (C), 125.0 (CH), 127.2 (CH), 128.3 
(C), 128.8 (2 × CH), 129.3 (CH, d, JC-C-C-F 3.5 Hz), 129.5 (C), 131.6 (CH), 131.8 (CH, d, JC-C-C-F 
8.0 Hz), 132.0 (2 × CH), 133.7 (CH), 133.8 (C), 134.5 (C, d, JC-C-C-C-F 3.5 Hz), 145.5 (C), 156.9 
(C, d, JC-F 248.3 Hz), 160.5 (C), 165.2 (C), 169.6 (C); HRMS (ESI) calcd for 
C27H22
79BrFN4NaO3 (MNa
+), 571.0752, found 571.0732. 
HPLC Methodology. All physicochemical analyses were performed using a Dionex Ultimate 
3000 series, and data acquisition and processing performed using the Chromeleon 6.8 
Chromatography software. The HPLC system was set to 25 °C, and UV detection achieved using 
a diode array detector (190±800 nm).  
 Lipophilicity (log Poct).  Compounds 1, 5 and 7±12 were dissolved in a 1:1 mixture of MeCN 
and 0.01 mM PBS to achieve a concentration of 0.5ԟ1.5 mg/mL. The mean retention time of 
each compound was measured three times using a reverse phase Phenomenex Luna 5 ȝm C18 
100Å (50 × 30 mm) column under the following mobile phase conditions: 0.0ԟͳͲ.5 min 100:0 to 
10:90 A:B, 10.5ԟ11.5 min 10:90 A:B, 11.5ԟ12.5 minutes 10:90 to 100:0 A:B, 12.5ԟ15.0 min 
100:0 A:B where A = PBS and B = MeCN. The mobile phase flow rate was 1.0 mL/min. Three 
separate experiments were performed using PBS pH 4.0, pH 7.4, and pH 10.0. The necessary pH 
was achieved by addition of either HCl 0.1% or 0.05 M NH4OH. A calibration regression model 
was generated by plotting the mean retention times (n = 3) against the known chromatographic 
hydrophobicity indices (CHIs) of the following standard compounds: theophylline (CHI = 
15.76), phenyltetrazole (CHI = 20.18), benzimidazole (CHI = 30.71), colchicine (CHI = 41.37), 
acetophenone (CHI = 64.90), indole (CHI = 69.15), and butyrophenone (CHI = 88.49).38 The 
CHI values of unknown compounds in the non-ionized state (CHIN) were obtained by fitting the 
mean retention times to the calibration regression model. The CHIN values were then converted 
to log Poct values using the below equation:
39
 
 
Log Poct = 0.047 CHIN + 0.036 HBC ± 1.10 
where CHIN = the chromatographic hydrophobicity index of the non-ionized compound, and 
HBC = hydrogen-bond donor count. All calculations were performed and plots were generated 
using the Microsoft Excel 2010 software. 
Percentage Plasma Protein Binding (%PPB). Compounds 1, 5 and 7±12 were dissolved in a 
1:3:3 mixture of MeCNP03%6DQG,3$WRDFKLHYHDFRQFHQWUDWLRQRI(?1.5 mg/mL. 
The mean retention time of each compound was measured three times using a ChromTech HSA 
 ȝP50 × 30 mm) column under the following mobile phase conditions: (씀3PLQWR
70:30 A:B, (씀1PLQ A:B, (씀1PLQWR $%(씀1PLQ
A:B where A = PBS (pH 7.4) and B = IPA. The mobile phase flow rate was 1.8 mL/min. The 
chromatographic system was calibrated using the following standard compounds of known 
%PPB: nizatidine (%PPB = 35.0), bromazepam (%PPB = 60.0), carbamazepine (%PPB = 75.0), 
budesonide (%PPB = 88.0), nicardipine (%PPB = 95.0), warfarin (%PPB = 98.0), ketoprofen 
(%PPB = 98.7%), indomethacin (%PPB = 99.0), and diclofenac (%PPB = 99.8%).39 The %PPB 
values of the standard compounds were converted to the linear free energy related log K values 
using the below equation:40 
/RJN ORJ33%·(씀 33% 
A calibration regression model was generated by plotting the mean retention times (n = 3) of the 
standard compounds against their corresponding log K values. The log K values of unknown 
compounds were then obtained by fitting the mean retention times to the calibration regression 
model, which were then converted to %PPB values using the below equation:40 
%PPB = (101 × 10log k) ÷ (1 + 10log k) 
All calculations were performed and plots were generated using the Microsoft Excel 2010 
software. 
Cell-free IC50. A commercially available Trevigen® colorimetric PARP assay was used to 
determine the activity of PARP-1 in the presence of varying concentrations of compounds 1, 5 
and 7±12 in 96-well histone coated plates; the assays were performed as per the manufacturer 
protocol. Briefly, the compounds were dissolved in EtOH followed by serial dilution with the 
 supplied PARP buffer in order to attain the desired assay concentrations; the final concentration 
of EtOH in each case was <1%. To the histone-coated wells containing inhibitor was added 0.5 
units of the supplied PARP enzyme diluted with PARP buffer. A positive control containing 
PARP enzyme in the absence of test compound and a negative control lacking PARP enzyme 
were also prepared. Following a 10 min incubation at room temperature a solution of PARP 
cocktail (containing biotinylated NAD+), activated (damaged) DNA, and PARP buffer (in a 1:1:8 
ratio) was introduced into each well using a multichannel pipette. The mixtures were incubated 
for 60 min at room temperature followed by four washes using 0.1% Triton X-100 in PBS. Each 
well was then incubated for a further 60 min at room temperature in the presence of the supplied 
Strep-HPR conjugate (diluted 500-fold) followed by four washes using 0.1% Triton X-100 in 
PBS. Finally, TACS-SapphireTM was introduced into each well and the colorimetric reaction was 
allowed to develop over 15 min at room temperature in the dark; the reaction was terminated by 
adding 0.2 M HCl. Absorbance measurements were performed at 450 nm using a Tecan Infinite 
M200 Pro microplate reader and were normalized to the positive and negative control values. 
The mean absorbance measurements were plotted against the corresponding log concentrations 
of each compound under investigation and a four-parameter logistic model was fitted to the 
resulting curves using the GraphPad Prism 6.0 software allowing for calculation of the IC50. The 
reported IC50 values for each compound were based on three experiments. 
Cell culture. *DQG7*KXPDQJOLREODVWRPDFHOOOLQHVZHUHFXOWXUHGLQ'XOEHFFR¶V0RGLILHG
Eagle Medium (DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine and 
1 mM sodium pyruvate and Minimum Essential Media (MEM) supplemented with 10% FCS and 
2 mM L-glutamine respectively. All cellular incubations were performed at 37 °C and 5% CO2 
unless stated otherwise. 
 Cellular IC50. Cells were seeded onto glass coverslips (19 mm dia.) in 12-well plates at 
concentrations of 8 × 104 (G7) or 5 × 104 (T98G) cells per well and were incubated for 48 h. The 
cells were then incubated for 60 min in cell media containing increasing concentrations of 
compounds 1 or 5. The compounds were dissolved in DMSO followed by serial dilution using 
PBS to generate the necessary stock solutions; the final dilutions used to attain the desired assay 
concentrations were performed using cell media and the final concentration of DMSO in each 
case was <1%. Next, the coverslips were incubated in 20 mM H2O2 in PBS in the dark, at room 
temperature for 10 min. A negative control containing media alone minus H2O2 treatment, and a 
positive control containing media alone plus H2O2 treatment were also used. The cells were 
washed with PBS and fixed with ice cold 4% formaldehyde in PBS for 15 min. Following 
fixation the cells were washed with PBS, permeabilized with 0.3% Triton X-100 in PBS for 10 
min at room temperature, and then washed three more times with PBS. The fixed cells were then 
incubated in 2% bovine serum albumin (BSA) in PBS for 30 min at room temperature. Primary 
antibody staining was performed using 1:200 anti-PADPR antibody (mouse antibody; ab14459; 
10H; Abcam) in KB buffer (10 mM Tris pH 7.5, 150 mM NaCl, 0.1% BSA) by incubating the 
coverslips on parafilm at room temperature for 60 min. The coverslips were washed once with 
PBS and twice with KB buffer and secondary staining was performed by using 1:500 anti-mouse 
antibody (goat anti-mouse antibody; Alexa Fluor 488; A11029; Life Technologies) in KB buffer 
by incubating the fixed cells at room temperature in the dark for 60 min. The coverslips were 
then washed three times with KB buffer and mounted onto glass slides using VectaShield® 
mounting medium. Immunofluorescence imaging was performed within 48 h of staining using a 
Zeiss LSM 710 confocal microscope. The following imaging parameters were used: 40 × 
magnification (oil); resolution = 512 × 512; tiling = 3 × 3; Z-stacking = 3±4 sections, image 
 depth = 12 bit. PARP activity was expressed as a ratio of poly(ADP-ribose) positive nuclei to the 
total number of nuclei; nuclei counted per well >120. Mean PARP activity was normalized to the 
positive and negative control values and plotted against the corresponding log concentrations of 
each compound under investigation. A four-parameter logistic model was fitted to the resulting 
curves using the GraphPad Prism 6.0 software allowing for calculation of the IC50. The reported 
IC50 values for each compound were based on two experiments. 
Plasma stability. Blood was harvested from female black-6 mice and to 0.5±1.0 mL of blood 
was added 75 ȝ/ of 0.5 M EDTA in dH2O. The blood was centrifuged at 5000 g for 5 min at 
room temperature and the plasma supernatant was isolated. To 50 ȝ/ of mouse plasma 
supernatant was added 10 ȝ/ RIȝ0 1 or 5 stock solution made in DMSO and dH2O such 
that the final assay concentration of DMSO was <1%. A negative control containing 50 ȝ/ of 
dH2O and 10 ȝ/ RIȝ0WHVWcompound minus plasma proteins was also used. The mixtures 
were incubated at room temperature for either 0 or 20 h, followed by addition of 200 ȝ/ of ice 
cold MeOH to precipitate the plasma proteins which were then isolated through centrifugation at 
2000 g for 5 min at room temperature. The supernatant (100 ȝ/) was diluted with 300 ȝ/ of a 
50:50 MeCN: dH2O solution and 10 ȝ/ of ȝ0LQWHUQDOVWDQGDUG (compound 13) was added. 
The resulting solution was passed WKURXJK D  ȝP ILOWHU DQG DQDO\]ed using liquid 
chromatography-mass spectroscopy, LC-MS (Shimadzu LC-2010AHT, LCMS-2010EV). LC 
was performed on 20 ȝ/ sDPSOHLQMHFWLRQVXVLQJD.LQHWH[ȝP;%-C18 100Å (50 × 4.60 mm) 
column and the following mobile phase conditions: 0.0±10.0 min 30:70 to 60:40 A:B, 10.0±12.0 
min 60:40 to 30:70 A:B, 12.0±14.0 min 30:70 A:B where A = MeCN and B = 0.1% formic acid 
in dH2O; flow rate 1.2 mL/min. The internal standard and parent compounds were detected using 
MS under the following conditions: positive ionisation; detector 1.50 kV; SIM m/z 551 (internal 
 standard: compound 13; MH+) and 597 (compound 5; MH+). Quantification was performed using 
the LabSolutions LCMS (Shimadzu Corporation) software by calculating the mean ratio of the 
area under the peak of the test compound to the internal standard. This ratio was then expressed 
as the percentage of parent compound (%parent) remaining relative to the negative control and a 
bar graph was plotted using the GraphPad Prism 6 software; error bars represent %parent 
remaining + standard deviation. The reported values for each compound were based on three 
experiments. 
Intrinsic Clearance (Clint). Aliquots ȝ/ of Gibco® pooled human liver microsomes from 
50 donors (20 mg/mL) were diluted with 100 mM KH2PO4 buffer (pH 7.4) such that the 
PLFURVRPDO FRQFHQWUDWLRQZDVPJP/7KHGLOXWHGPLFURVRPDO HQ]\PHVWRFN ȝ/ZDV
added to ȝ/RI 100 mM KH2PO4 buffer (pH 7.4) followed by ȝ/RI ȝ0 1 or 5 in a 
mixture of DMSO and 100 mM KH2PO4 buffer (pH 7.4) such that the final assay concentration 
RI'062ZDV7KHVROXWLRQVZHUHZDUPHGWR°C for 10 min followed by addition of 20 
ȝ/RI 13 mM NADPH stock in 100 mM KH2PO4 buffer (pH 7.4). A negative control was used 
which contained ȝ/RI the diluted microsomal enzyme stock, ȝ/RIȝ0WHVWFRPSRXQG 
solution and  ȝ/ RI 100 mM KH2PO4 buffer (pH 7.4) minus NADPH. Incubations were 
terminated 0, 5, 15, 30 and 45 min after NADPH addition by LQWURGXFLQJ  ȝ/ RI MeCN 
which precipitated the microsomal enzymes. The suspensions were centrifuged at 1000 g for 5 
min at room temperature and  ȝ/ RI the supernatant was removed from each sample and 
diluted with  ȝ/ RI MeCN followed by the addition of  ȝ/ RI  ȝ0 LQWHUQDO VWDQGDUG 
(compound 13 for compound 5 or papaverine for compound 1). The resulting solutions were 
passed through D  ȝP ILOWHU DQG ZHUH DQDO\]ed using LC-MS (Shimadzu LC-2010AHT, 
LCMS-(9/&ZDVSHUIRUPHGRQȝ/VDPSOHLQMHFWLRQVXVLQJD.LQHWH[ȝP;%-C18 
 100Å (50 × 4.60 mm) column. The mobile phase conditions were dependant on the test 
compound: i) 5 0.0±10.0 min 30:70 to 60:40 A:B, 10.0±10.5 min 60:40 to 90:10 A:B, 10.5±12.0 
min 90:10 A:B, 12.0±12.5 min 90:10 to 30:70 A:B, 12.5±15.0 min 30:70 A:B; and ii) 1 0.0±10.0 
min 20:80 to 55:45 A:B, 10.0±12.0 min 55:45 to 20:80 A:B, 12.0±14.0 min 20:80 A:B where A 
= MeCN and B = 0.1% formic acid in dH2O; flow rate 1.2 mL/min. The internal standards and 
parent compounds were detected using MS under the following conditions: positive ionisation; 
detector 1.50 kV; SIM m/z 551 (internal standard: compound 13; MH+), 597 (compound 5; 
MH+), 340 (internal standard: papaverine; MH+), 435 (compound 1; MH+). Quantification was 
performed using the LabSolutions LCMS (Shimadzu Corporation) software by calculating the 
ratio of the area under the peak of the test article to the internal standard. This ratio was then 
expressed as the ln % of parent remaining relative to the 0 min incubation timepoint. Ln % of 
parent remaining over time plots were generated using the GraphPad Prism 6 software and linear 
regression models were used to calculate the Clint of the test compound using the following 
equations:27 
i) k = gradient 
ii) t1/2 (min) = ln(2)/k 
LLL9Gȝ/mg) = YROXPHRILQFXEDWLRQȝ/·protein in incubation (mg) 
iv) Clint ȝ/min/mg of protein) = (Vd × ln(2)) ÷ t1/2 
where k = elimination rate constant, t1/2 = half-life, and Vd = volume of distribution. The reported 
Clint values for each compound were based on two experiments. 
Radiochemistry. A 2.00 mL v-vial was half-filled with 3 mm borsilicate glass beads and to that 
was added 100 ȝ/ of 0.492 M (NH4)2SO4 solution in dH2O and 100 ȝ/ of 1.68 mM solution of 
 precursor 13 in glacial acetic acid. The mixture was vortexed and then 35.5±175.0 MBq of [123I]-
NaI in 50.0 mM NaOH was added; the edges of the v-vial were rinsed with 150 ȝ/ of 
EtOH:dH2O (1:2). Solvents were removed by passing a constant stream of argon over the 
solution at 150 °C and aliquots of anhydrous MeCN (3 × 500 ȝ/) were added to facilitate 
azeotropic drying (approx. 30 min). The argon supply was removed and the sealed v-vial was 
heated to 210 °C. Once at the correct temperature, 8 mL of air was injected and the reaction was 
heated for a further 30 min. The contents of the v-vial were allowed to cool to room temperature 
and the organic components were dissolved in 300 ȝ/ of MeCN followed by the addition of 150 
ȝ/ of MeCN:dH2O (3:7). The crude [123I]-5 reaction mixture was loaded onto a Phenomenex 
6\QHUJL  ȝP +\GUR-RP 80Å (150 × 10.00 mm) column. Purification was achieved using a 
Dionex Ultimate 3000 HPLC system and the following mobile phase conditions: 0.0±30.0 min 
30:70 A:B to 55:45 A:B where A = MeCN and B = dH2O; flow rate 3.0 mL/min. Detection was 
achieved using a Knauer Advanced Scientific Instruments Smartline UV Detector 2500 (254 nm) 
and a photomultiplier tube connected to a Lab Logic Flow-Count radiodetector. The radiolabeled 
product was collected at approximately 27.0 min and concentrated in vacuo in an evaporator 
flask. The flask was rinsed with MeCN (3 × 300 ȝ/) to extract the radiolabeled compound and 
the solution was transferred to a 2.00 mL v-vial; the solvent was removed by passing a constant 
stream of argon over the solution at 100 °C (approx. 15 min). The radiotracer was then 
reconstituted in up to 900 ȝ/ of a 10% EtOH in 0.9% saline solution. Since the amount of 
radiolabeled product that was produced fell below the sensitivity threshold of the UV detector 
(<1.68 × 10-4 µmol), specific activity (Ci/µmol) was calculated using the lowest detectable 
amount of non-labelled 5 established from a calibration plot of a range of concentrations (0.001±
1.000 mg/mL). The identity of the radiolabeled product was confirmed by performing quality 
 control analysis of a sample of the formulated radiotracer using a Dionex Ultimate 3000 HPLC 
system and a PKHQRPHQH[6\QHUJLȝP+\GUR-RP 80Å (150 × 4.60 mm) column. The same 
mobile phase conditions were used as described above for the HPLC purification step. 
Radiodetection was achieved using a Berthold Technologies Flow Star LB513 detector. All 
HPLC analyses were performed using the Chromeleon 6.8 Chromatography software. 
Mouse Glioma Model. Female 7±11 week old CD1 nude mice had 5 × 106 U87MG-Luc2 cells 
injected subcutaneously into the right flank. The U87MG-Luc2 cells were originally derived 
from a glioblastoma (stage IV) in a 44 year old male Caucasian patient; the cell line was 
purchased commercially from ATCC. The animal subcutaneous xenografts were measured and 
monitored visually every three days. Tumor bearing animals were used for in vivo studies 21±30 
days post-implantation. 
Ex vivo Biodistribution. Subcutaneous tumor bearing mice received bolus tail vein injections of 
0.8±1.1 MBq [123I]-5 in 0.15±0.25 mL 10% EtOH in 0.9% saline. The animals were sacrificed by 
CO2 asphyxiation either 30 min (n=3), 60 min (n = 4) or 120 min (n=4) following tracer 
injection. The following tissue and material were harvested and transferred to pre-weighed 1.5 
mL Eppendorf vials containing 0.5 mL of fixative (4% formaldehyde in PBS) immediately after 
sacrifice: i) blood, ii) spleen, iii) stomach matter, iv) stomach tissue, v) small bowel matter, vi) 
small bowel tissue, vii) caecum matter, viii) large bowel tissue, ix) solid faeces, x) pancreas, xi) 
liver (left lobe), xii) kidney (left), xiii) heart, xiv) lung (left lobe), xv) muscle (left femur), xvi) 
femur (left), xvii) brain, and xviii) tumor. Each vial was weighed and gamma counted using a 
Cobra II Auto-Gamma® counter using the following parameters: count time = 1 min; KeV range 
= 136±215; output = counts per min (CPM). A positive control was used containing 0.5 mL of 
IL[DWLYHDQGȝ/RIWKH>123I]-5 stock solution used to dose the animal. Background counts were 
 defined using a negative control containing 0.5 mL of fixative. The background signal was 
subtracted and the CPM were normalized to the weight of each tissue or matter sample. The 
CPM of each positive control were then used to calculate the theoretical maximum CPM of each 
injected tracer volume and this was in turn used to calculate the percentage injected dose per 
gram of tissue or matter (%ID/g). Calculations were performed using the Microsoft Excel 2010 
software. The mean %ID/g acquired for each tissue or material was plotted on a bar chart using 
the GraphPad Prism 6.0 software; error bars represent the %ID/g + SD. 
Ex vivo Biodistribution pre-blockade. Subcutaneous tumor bearing mice received an 
intraperitoneal injection of either vehicle (13.5% DMSO and 10% 2-hydroxy-ȕ-cyclodextrin in 
dH2O) (n = 3) or 50 mg/kg of compound 1 in vehicle 20 min prior to intravenous tail vein 
injection of 0.8±1.1 MBq [123I]-5 in 0.18±0.25 mL 10% EtOH in 0.9% saline. The animals were 
sacrificed by CO2 asphyxiation 60 min after tracer injection, and tumor and muscle tissues were 
immediately harvested and transferred to pre-weighed 1.5 mL Eppendorf vials containing 0.5 mL 
of fixative (4% formaldehyde in PBS). Each vial was gamma counted and the %ID/g values were 
calculated as described earlier. The data were plotted on a bar chart as the ratio of %ID/g of 
tumor to muscle tissue using the GraphPad Prism 6.0 software; error bars represent the %ID/g + 
SD. 
Immunohistochemistry. Tumor and muscle tissues were immersion fixed in 4% formaldehyde 
for 48 h. The fixed tissues were embeded in SDUDIILQEORFNVDQGȝPVHFWLRQVZHUHFXW3DUDIILQ
was removed by incubating the tissue sections in xylene (2 × 5 min) followed a 5 step 
rehydration using 100% EtOH (1 min and 5 min), 70% EtOH (2 × 5 min) and water (5 min). 
Immunohistochemistry was performed using the Dako EnVisionTM kits. Briefly, heat induced 
antigen retrieval using Dako Cytomation Target Retrieval Solution (pH 6.0) was followed by an 
 incubation in 3% H2O2 in MeOH (20 min), and then 5% BSA and 5% goat serum in PBS (20 
min) to block peroxidase activity and minimize non-specific binding respectively. Between each 
step the tissue sections were washed in 0.1% Tween® 20 in TBS (2 × 5 min). The tissue sections 
were incubated overnight at 4±8 °C in 1:100 anti-PARP-1 antibody (mouse anti-human and 
mouse antibody; sc-8007; Santa Cruz). Following this, the tissue was washed with 0.1% 
Tween® 20 in TBS (2 × 5 min) and a secondary one hour incubation at room temperature was 
performed using Dako horseradish-peroxidase labeled anti-mouse polymer. The sections were 
once again washed using 0.1% Tween® 20 in TBS (2 × 5 min) and the presence of antibody was 
GHWHFWHG XVLQJ D ¶-diaminobenzidine chromagen solution diluted in Dako DAB+ substrate 
buffer. Haematoxylin and eosin staining was performed using a Leica ST5020 multistainer. 
Histology images were acquired using a Zeiss AX10 brightfield microscope at ×4 magnification 
and contrast was corrected manually using the ImageJ 1.47v software. 
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Tables, Figures and Schemes.  
 
 
Figure 1. The clinical PARP-1 inhibitor olaparib.  
 
 
Figure 2. PARP-1 PET imaging tracers currently in development.13±15  
  
Table 1. Approach used to access 1 and analogs 5 and 7±12, from the penultimate compound 6, 
as well as the cell-free PARP-1 inhibitory and physiochemical properties of these compounds.  
 
Reagents and conditions: (a) HBTU, Et3N, DMF, rt, 72 h; (b) HBTU, Et3N, DMF, rt, 48 h; (c) 
HBTU, Et3N, DMF, 40 °C, 22 h; (d) Et3N, CH2Cl2, rt, 6 h. 
 aCell-free IC50 values are based on three experiments. 
bLipophilicity (log Poct) was determined 
using a C-18 reverse phase HPLC column. cPercentage plasma protein binding (%PPB) was 
determined using a human serum albumin coated HPLC column. dThe exact log Poct could not be 
calculated as the value exceeded the assay limit.  
 
Table 2. Cellular PARP-1 inhibitory, and mouse plasma and metabolic stability properties of 
compounds 1 and 5. 
 
aCellular IC50 values obtained using primary G7 and established T98G human glioblastoma cell 
lines are based on two experiments. bThe mean percentage of parent compound remaining after a 
20 h incubation in mouse plasma (± SD of three experiments) was ascertained for compound 5. 
cIntrinsic clearance (Clint) values are the mean ± SD of two experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3. Optimization of the solid state halogen exchange radioiodination methodology using 
brominated precursor 13.  
 
aCalculated from the radio-HPLC trace following a single reaction. 
 
Scheme 1. Optimized radioiodination approach used to generate [123I]-5. 
 
 
  
Figure 3. Ex vivo biodistribution of [123I]-5 in subcutaneous human glioblastoma bearing nude 
mice 30 min (n = 3), 60 min (n = 4) and 120 min (n = 4) after tracer injection. Error bars 
represent the mean percentage of injected dose per gram of tissue or material (% ID/g) + SD.  
 
 
 
 
 
 
 
 
 
Figure 4. Representative immunohistochemistry images of a U87MG-Luc2 subcutaneous tumor 
(a) and muscle tissue (b) stained for the cell proliferation marker Ki67 and PARP-1. The tissues 
were counterstained with hematoxylin. Brown staining signifies presence of marker and dark 
blue staining shows cellular nuclei. 
PARP-1 Ki67 
(b) 
(a) 
  
Figure 5. Ratio of percentage of injected dose per gram (%ID/g) of tumor to muscle of [123I]-5 
60 min after injection in subcutaneous human glioblastoma bearing nude mice pre-treated with 
either vehicle (n = 3) or 50 mg/kg compound 1 (n = 3). Error bars represent the mean + SD. 
Unpaired t test: P = 0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table of Contents graphic.  
 
 
